prednisolone / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

10 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
prednisolone / Generic mfg.
2019-003197-24: Study of the effect of PL-8177 on inflammatory onset and resolution in Healthy Volunteers

Not yet recruiting
2
45
Europe
prednisolone, PL8177, Solution for injection in pre-filled syringe, Tablet, Prednisolone Tablets BP 5mg
Palatin Technologies, Inc., Palatin Technologies, Inc.
Inflammatory Onset and Resolution, Blister induction and effect of PL8177 on inflammation, Body processes [G] - Immune system processes [G12]
 
 
2021-004323-33: A Study to Evaluate the Efficacy, Safety and Tolerability of a Single Injection of AC102 into the Middle Ear Compared to Oral Steroid Treatment in Patients with Sudden Hearing Loss.

Not yet recruiting
2
210
Europe, RoW
-, Prednisolone 10 mg GALEN Tablets, AC102, Gel for injection, Tablet, Prednisolone 10 mg GALEN Tablets
AudioCure Pharma GmbH, Audiocure Pharma GmbH
Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)ISSNHL is most commonly defined as sensorineural hearing loss of 30dB or greater over at least three contiguous audiometric frequencies occurring within a 72-hr period.Inclusion within this trial applies for moderately severe to profound cases ( 65 to <100 dB) within 24 to 120 hours after onset., Condition when a person suddenly can not hear anymore on one ear without a clear reason., Diseases [C] - Ear, nose and throat diseases [C09]
 
 
NCT06474442: A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis

Not yet recruiting
2
40
RoW
BD111 Injection (investigational new drug), BD111 Lentivirus-like particles, also called HSV-1-erasing lentiviral particles (HELP), Triple-drugs therapy of HSV-1 stromal keratitis, Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops
Shanghai BDgene Co., Ltd.
Herpes Simplex Virus Type I Stromal Keratitis
12/25
12/26
NCT05776459: Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)

Recruiting
2
210
Europe, RoW
AC102 gel, Prednisolone, Placebo Tablets, Placebo gel
AudioCure Pharma GmbH
Hearing Loss, Sensorineural
10/24
12/24
waveLINE-007, NCT05406401 / 2021-005861-41: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Recruiting
2
60
Europe, Canada, RoW
Zilovertamab Vedotin, MK-2140, VLS-101, Cyclophosphamide, CYTOXAN®, NEOSAR®, Doxorubicin, ADRIAMYCIN®, Rituximab, RITUXAN®, Rituximab Biosimilar, TRUXIMA®, Prednisone, Prednisolone
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Lymphoma, Large B-Cell, Diffuse (DLBCL)
01/26
01/26
2020-002021-28: A Study to Evaluate PLX2853 in Combination with Abiraterone Acetate/Prednisone and PLX2853 in Combination with Olaparib in Subjects with Metastatic Castration-Resistant Prostate Cancer

Not yet recruiting
1/2
110
Europe
PLX2853, Abiraterone Acetate, Prednisolone, PLX2853, Tablet, ZYTIGA, PREDNISOLONE
Plexxikon Inc., Plexxikon Inc.
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Castration-Resistant Prostate Cancer, Diseases [C] - Cancer [C04]
 
 
NCT03586999: Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

Active, not recruiting
1/2
18
US
Nivolumab, Opdivo, Etoposide, Vepesid, Toposar, Prednisolone, Oraped, PediaPred, Millipred, Oncovin, Vincristine, Leurocristine, Cyclophosphamide, cytophosphane, Hydroxydaunorubicin, Adriamycin
University of Colorado, Denver, Bristol-Myers Squibb
Peripheral T Cell Lymphoma
09/22
12/24
Epi-RCHOP, NCT02889523 / 2016-001499-31: Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy

Calendar Jan 2023 - Dec 2024: Data from P1b/2 trial for DLBCL and follicular lymphoma
Checkmark Initial combination data
Dec 2018 - Dec 2018: Initial combination data
Not Appicable May 2018 - May 2018 : Epi-RCHOP trial in 1L DLBCL [Trial suspended]
Checkmark Transition into P2 in P1/2 Epi-RCHOP trial in frontline DLBCL
More
Active, not recruiting
1/2
214
Europe
Tazemetostat, EPZ-6438, Rituximab, Mabthera, Cyclophosphamide, Vincristine, Doxorubicin, Prednisolone
The Lymphoma Academic Research Organisation, Epizyme, Inc.
Lymphoma, DLBCL, Follicular Lymphoma
01/23
04/26
COALITION, NCT04914741: A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

Active, not recruiting
1/2
80
RoW
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Glofitamab, RO7082859, CD20-TCB, Polatuzumab vedotin
Peter MacCallum Cancer Centre, Australia, Hoffmann-La Roche
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
01/24
07/25
MORAb-202-G000-201, NCT04300556: A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Recruiting
1/2
142
Europe, US
Farletuzumab ecteribulin, MORAb-202, Prednisone, Prednisolone, Dexamethasone
Eisai Inc., Bristol-Myers Squibb
Solid Tumor
03/25
03/25

Download Options